RxDoctor Payments Data

Brian Peterson, MD

Neurology · Metairie, LANPI 1639330996

Payments from drug & device makers

$8,581in general payments, 2019–2025

Across 465 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$688
  • Argenx US, Inc.$537
  • Novartis$442
  • Acadia Pharmaceuticals Inc$425
  • Lilly USA, LLC$414
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$8,581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,581 in reported general payments places this provider in the 65th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$63,091
Medicare patients
173
Services billed
723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4663$296,415
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$53,242
FycompaPerampanel32$49,044
QuliptaAtogepant37$46,718
Nurtec OdtRimegepant Sulfate23$42,380
EliquisApixaban39$22,862
Aimovig AutoinjectorErenumab-Aooe12$12,989
Lacosamide73$5,811
DilantinPhenytoin Sodium Extended18$5,173
Levetiracetam181$3,843
Gabapentin264$3,713
Tegretol XrCarbamazepine11$3,189
Memantine Hcl161$3,011
Ropinirole ErRopinirole Hcl24$2,738
Carbidopa-LevodopaCarbidopa/Levodopa111$2,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$279$296,41563 claims
PfizerNurtec Odt, Eliquis, Dilantin, Dilantin$274$70,95992 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$56$53,24212 claims
Eisai Inc.Fycompa$313$49,04432 claims
AbbVieQulipta$1,538$46,71837 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$241$1,55815 claims
Upsher-smith Laboratories LLCTopiramate$33$34045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 225 neurology providers in Louisiana.

Other neurology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →